Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Københavns Universitets forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Profiler
Publikation
Forskningsenheder
Presse/medier
Aktiviteter
Priser
???studenttheses???
Forskningsdatasæt
Søg efter ekspertise, navn eller tilknytning
C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma
Benedikte Jacobsen,
Mette Camilla Kriegbaum
, Eric Santoni-Rugiu,
Michael Ploug
6
Citationer (Scopus)
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Medicine and Dentistry
Biological Marker
100%
Squamous Cell Carcinoma
100%
Lung
100%
Invasive Carcinoma
100%
Carcinoma in Situ
100%
Lung Adenocarcinoma
100%
Squamous Epithelium
100%
Dysplasia
50%
Atypical Adenomatous Hyperplasia
50%
Carcinoma
50%
Tumor Progression
50%
Solid Malignant Neoplasm
50%
Non Small Cell Lung Cancer
50%
Adenocarcinoma
50%
Prognostic Factor
50%
Predictive Factor
50%
Prevalence
50%
Hyperplasia
50%
Mucin
50%
Lung Cancer
50%
Tumor Suppressor Protein
50%
Metaplasia
50%
Stratified Squamous Epithelium
50%
Keyphrases
Pulmonary Adenocarcinoma
100%
C4.4A
100%
Squamous Cell Carcinoma (SqCC)
100%
Adenocarcinoma Cells
100%
Invasive Carcinoma
33%
Squamous Epithelium
33%
Liver Kinase B1 (LKB1)
33%
Solid Tumors
16%
Lung Cancer
16%
Atypical Hyperplasia
16%
Mucus Production
16%
Hyperplasia
16%
High Mortality
16%
In Situ Carcinoma
16%
Membrane Protein
16%
Lung Adenocarcinoma
16%
Predictive Factors
16%
Patient Survival
16%
Stratified Epithelium
16%
High Prevalence
16%
Physiological Condition
16%
Tumor Growth Pattern
16%
Carcinoma
16%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
16%
Suprabasal
16%
Patient Treatment
16%
Prognostic Impact
16%
Tumor Suppressor
16%
Lung Carcinoma
16%
Carcinoma in Situ
16%
Prognostic Factors
16%
5-year Survival
16%
Dysplasia
16%
Treatment Efficacy
16%
Non-small Cell Lung Cancer (NSCLC)
16%
Targeted Treatment
16%
Metaplasia
16%